Ann: March 2025 Quarterly Activity Report and Appendix 4C, page-8

  1. 3,236 Posts.
    lightbulb Created with Sketch. 867
    With the P1a dosing regime and focus on safety, and not optimal dosing it has me questioning how much cpacs/mopacs data we will get. There is no doubt Bis is an anti cancer drug. This will not move the dial. Sorry should've worded my Q better- Do we have to wait until P1b to get the juice that will awaken the market via CPAcs in human validation?

    Thank you @Dprent

    No e the less. Dosing someone end of June is not good enough
    Last edited by HeyLine: 23/04/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.20
Change
0.015(1.27%)
Mkt cap ! $208.4M
Open High Low Value Volume
$1.20 $1.20 $1.17 $139.7K 118.3K

Buyers (Bids)

No. Vol. Price($)
1 666 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.20 7691 3
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.